What To Look For In An Oncology CRO: A Guide For Sponsors In 2025
By Kris O’Brien, VP, Oncology and Rare Diseases
In its annual January report, the American Cancer Society forecasts that approximately 2.2 million new cancer cases will be diagnosed in the U.S. in 2025, with over 618,000 cancer-related deaths. Despite a continued decline in cancer mortality through 2022, 2025 will bring new advancements and obstacles in oncology clinical research. To further progress towards a cancer-free future, oncology sponsors must strategically select contract research organization (CRO) partners.
This article outlines seven critical factors for choosing an oncology-focused CRO, enabling sponsors to identify partners that align with their clinical research objectives and enhance the likelihood of clinical trial success.
- Specialized Expertise and Successful Track Record in Oncology Clinical Development
- Robust Technological Infrastructure and Data Management Capabilities
- Oncology CRO with Global Reach and Quality Site Relationships
- Commitment to Strategic Innovations for Patient-Focused Oncology Trials
- Quality Management and Regulatory Compliance in Cancer Clinical Trials
- Oncology CRO with Operational Excellence and Efficient Project Management
- Financial Stability and Resource Allocation During Oncology Clinical Development
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.